Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01779778 · ClinicalTrials.gov registry record
Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure
A clinical trial of Ocular Hypertension and Open Angle Glaucoma, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT01779778 is a study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01779778, a study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the diurnal and nocturnal effects of Travoprost with SofZia (Travatan Z) on intraocular pressure and ocular perfusion pressure.
Conditions Studied
Study Locations (1)
Colorado
- University of Colorado Eye Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01779778
The ClinicalTrials.gov registry entry for NCT01779778 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (86% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT01779778 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01779778 about?
NCT01779778 is a clinical study titled "Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure". The purpose of this research study is to determine the diurnal and nocturnal effects of Travoprost with SofZia (Travatan Z) on intraocular pressure and ocular perfusion pressure.
What is the current status of trial NCT01779778?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2012-04. Estimated completion is 2013-04.
What conditions does trial NCT01779778 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
Who is sponsoring clinical trial NCT01779778?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01779778 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.